Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies expands its collaboration
with the U.S. Department of Health & Human Services’ Biomedical
Advanced Research and Development Authority (BARDA) aimed at
accelerating the development of a vaccine against the coronavirus
causing the current outbreak, COVID-19 (formerly 2019-nCoV).
Janssen and BARDA will both fund R&D costs and
mobilize resources to more rapidly progress through the initial stages
of development. BARDA will provide funding to support development into
Phase 1 studies with options to provide additional funding to advance a
promising candidate.
In parallel, Janssen will work to upscale production and manufacturing capacities, leveraging its AdVac and PER.C6 technologies.
Shares up 1% after hours.
https://seekingalpha.com/news/3540807-j-and-j-teams-up-barda-to-accelerate-coronavirus-vaccine-development
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.